Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
Transfus Apher Sci
; 60(5): 103197, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1275746
ABSTRACT
High-dose chemotherapy followed by autologous stem cell transplantation is a major component in the treatment of patients with multiple myeloma. As a prerequisite, the successful collection of a sufficient number of viable peripheral blood hematopoietic CD34+ cells is critical. A common standard protocol for mobilization is currently not defined and critically discussed especially in German-speaking Europe. In times of the Covid-19 pandemic, safe and effective strategies have to be chosen to minimize hospitalization times and severe courses. In this single-center retrospective analysis, safety and efficacy of cyclophosphamide plus etoposide (CE) and growth-factor support (n = 33) was compared to cyclophosphamide mono treatment and growth-factor support (n = 49) in 82 patients with multiple myeloma at first diagnosis. CE was superior to cyclophosphamide mono with a significantly higher number of collected CD34+ cells (15.46 × 106 CD34+ cells/kg vs. 9.92 × 106 CD34+ cells/kg), significantly faster engraftment of granulocytes after stem cell transplantation (day 10.5 vs. day 11.6), shorter duration of the inpatient stay (17.47 days vs. 19.16 days) and significantly less transfusions (8.82 % vs. 30.61 % patients receiving transfusions). The safety profile was comparable in both groups and in line with published data. We conclude that CE is a safe and highly effective mobilization protocol in patients with multiple myeloma at first diagnosis and appears to be superior to the commonly used cyclophosphamide mono regimen.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hematopoietic Stem Cells
/
Antineoplastic Combined Chemotherapy Protocols
/
Hematopoietic Stem Cell Mobilization
/
Cyclophosphamide
/
Peripheral Blood Stem Cell Transplantation
/
Etoposide
/
Multiple Myeloma
Type of study:
Experimental Studies
/
Observational study
/
Randomized controlled trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Transfus Apher Sci
Journal subject:
Hematology
Year:
2021
Document Type:
Article
Affiliation country:
J.transci.2021.103197
Similar
MEDLINE
...
LILACS
LIS